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Background
Studies on the relation between thrombin activatable fibrinolysis inhibitor (TAFI) and arte-
rial thrombosis have produced conflicting results.TAFI regulates fibrinolysis, but other
roles of this inhibitor, including anti-inflammatory properties, have also been demonstrat-
ed. 
Design and Methods
We investigated the association between TAFI activity and the risk of myocardial infarc-
tion. Additionally, we studied the association of common single nucleotide polymor-
phisms in the TAFI gene with levels of the TAFI protein and risk of myocardial infarc-
tion.We included 554 men under 70 years old with a first myocardial infarction and 643
controls participating in the Study of Myocardial Infarctions Leiden (SMILE), a case-con-
trol study.
Results
We found odds ratios (95% confidence intervals) of a first myocardial infarction of 2.4
(1.6-3.6), 3.2 (2.1-4.7) and 3.4 (2.3-5.1) for subjects whose TAFI levels were in the third,
second and first quartiles (lowest TAFI levels), respectively, compared with the fourth
quartile, after adjusting for arterial disease risk factors. The rare -438A and 1040T alleles
were associated with lower, and the rare 505G allele with higher TAFI levels than the com-
mon alleles. Carriers of the -438A allele had an increased risk of myocardial infarction
(odds ratio 1.6 (1.0-2.5) for AA; odds ratio 1.2 (0.9-1.5) for AG compared with GG). The
other single nucleotide polymorphisms were not associated with myocardial infarction. 
Conclusions
Low TAFI activity levels are associated with increased risk of a first myocardial infarction
in men. The results on the association between TAFI single nucleotide polymorphisms and
myocardial infarction were inconsistent.
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Introduction
Thrombin activatable fibrinolysis inhibitor (TAFI)
forms the molecular link between the coagulation and
fibrinolytic systems.1 Various animal models have
demonstrated that TAFI regulates both venous and
arterial fibrinolysis in vivo.2-5 Furthermore, epidemiolog-
ical studies have shown elevated TAFI levels to be a
mild risk factor for the development of a first or recur-
rent venous thrombosis.6-8 However, studies on the
association between single nucleotide polymorphisms
(SNP) that are associated with TAFI levels and the risk
of venous thrombosis have given conflicting results.9-11
Epidemiological data on the association between
TAFI levels and the risk of arterial disease are inconsis-
tent. Several case-control studies have shown high
TAFI levels to be associated with the risk of coronary
artery disease.12-14 However, elevated TAFI levels, or
polymorphisms in the TAFI gene associated with
increased TAFI levels, have been related to a decreased
risk of myocardial infarction.15 In one case-control
study, high TAFI antigen decreased but high TAFI activ-
ity increased the risk of myocardial infarction in young
patients.16 Furthermore, in a prospective study,
decreased TAFI levels were associated with refractive-
ness to medical treatment in patients with unstable
angina pectoris.17
Recently, biological functions of TAFI distinct from
fibrinolysis regulation have been described, including
regulation of inflammation, blood pressure, cell migra-
tion, and wound healing.18 These functions may
depend on substrates of TAFI other than fibrin, for
instance bradykinin, the anaphylatoxins C3a and C5a,
annexin II, and osteopontin.19,20
The contradictory results from epidemiological stud-
ies may be explained by two opposite effects of TAFI
on the development of arterial thrombosis. While the
association between high levels of TAFI and arterial
thrombosis may be the result of a hypofibrinolytic
state, the association between low TAFI levels and arte-
rial thrombosis may be explained by a defective regula-
tion of inflammation.
Another explanation of the contradictory results
could be the use of different methods for measuring
TAFI. Several different antigen assays as well as distinct
activity assays have been used in epidemiological stud-
ies. With the discovery that some enzyme linked
immunosorbent assays of TAFI antigen are dependent
on the 1040C/T polymorphism, revealing a lack of
reactivity with the 1040T variant,21 even more caution
is required in the interpretation of results.
The -438G/A SNP in the promoter region of the TAFI
gene,22 the 505G/A SNP (which encodes an Ala to Thr
substitution at position 147),22 and the 1040C/T SNP
(encoding a Thr to Ile substitution at position 325)23 are
known to be associated with TAFI plasma antigen lev-
els. In Caucasians, three main haplotypes can be iden-
tified (www.hapmap.org). The -438G/A and 1040C/T
are generally located in the same haplotype, but are not
in complete linkage disequilibrium.24 The 505A/G is
typical to a second haplotype. A third haplotype is
characterized by a fourth SNP in intron 4 (i4 + 164
A/C). In the Study of Myocardial Infarctions Leiden
(SMILE), a case-control study of men with a first
myocardial infarction, we investigated determinants of
the level of TAFI. In addition we studied the effect of
plasma TAFI levels, as determined by a functional
assay, and the -438G/A, 505A/G, 1040C/T, and i4 +
164A/C SNP in the TAFI gene on the risk of a first
myocardial infarction.
Design and Methods
Selection of participants
The design of SMILE has been described previously.25
In brief, the recruited patients were men who had a
first myocardial infarction between January 1990 and
January 1996, who were below the age of 70. Control
subjects were frequency matched on 10-year age
groups to the patients and were men without a history
of myocardial infarction, without renal disease or
severe (neuro)psychiatric problems, with a life
expectancy of more than 1 year, and who had not taken
any oral anticoagulants in the 6-month period prior to
participation in the study. All participants completed a
questionnaire and an interview took place prior to col-
lection of blood samples. Questions referred to present
and former smoking habits and alcohol use, diabetes,
and current use of medications. Blood pressure was
measured after a rest of at least 10 min with the person
sitting in an upright position. In addition, for patients,
information on diabetes and medication use prior to
myocardial infarction was retrieved from discharge let-
ters. A person was classified as hypertensive or hyper-
cholesterolemic when he was taking prescription drugs
for these conditions. All participants signed an
informed consent form. Approval for this study was
obtained from the the Medical Ethics Committee of the
Leiden University Medical Center, Leiden, The
Netherlands.
Blood collection and laboratory analysis
Fasting blood samples were drawn from the antecu-
bital vein into Sarstedt Monovette tubes (Sarstedt,
Nümbrecht, Germany) and were obtained between
July 1994 and February 1997. Most blood samples were
collected in the morning (at a median of 9:35 am, with
95% before 11:00 am). The time between myocardial
infarction and blood sampling ranged from 88 days to
5.8 years with a median of 2.6 years.
Total cholesterol, HDL-cholesterol, triglyceride, and
C-reactive protein (CRP) concentrations were meas-
ured as described previously.25
Plasma TAFI activity levels were determined in citrat-
ed plasma with a chromogenic assay (Pefakit TAFI,
Pentapharm Ltd., Basel, Switzerland) by converting
TAFI into its active form using a reagent containing
thrombin-thrombomodulin and subsequently measur-
ing carboxypeptidase activity. Measurements were run
on a BCS coagulation analyzer (Dade Behring Inc.,
Marburg, Germany). TAFI activity was expressed in
percentages using a calibration curve of pooled normal
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plasma (pool of samples from more than 200 healthy
volunteers). The inter-assay coefficients of variation
were 5.8% (n=32) at ~100% TAFI concentration and
8.0% (n=31) at ~28% TAFI concentration. For six
patients and three control subjects, plasma was unavail-
able or reliable results were not obtained; therefore 554
patients and 643 control subjects were included in the
analysis. 
The -438G/A (rs2146881), i4 + 164 A/C (rs3818477),
505G/A (rs3742264), and 1040C/T (rs1926447) poly-
morphisms were determined by a 5’nuclease assay
(Taqman; Applied Biosystems, Foster City, CA) using a
standard polymerase chain reaction (PCR) mix
(Eurogentec, Seraing, Belgium) and allele-specific fluo-
rescent probes equipped with a minor groove binding
moiety (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Mean TAFI levels were calculated with 5th and 95th
percentiles for categories of arterial risk factors.
Quartiles of continuous variables (blood pressure, total
cholesterol, HDL-cholesterol, triglyceride, and CRP)
were defined based on the distribution among control
subjects. A multiple linear regression analysis was per-
formed among the control subjects to determine the
independent effect of arterial risk factors on TAFI levels.
As the association between lipid levels or CRP and TAFI
is not linear, these variables were entered in the model
using quartiles.
The association between TAFI levels and the risk of a
first myocardial infarction was investigated by calculat-
ing odds ratios (OR), as an approximation of relative
risks, and 95% confidence intervals (CI). TAFI levels
were grouped into quartiles based on the distribution
among the control subjects. The highest quartile (high-
est TAFI levels) was taken as the reference group. OR
adjusted for age and other potential confounders were
calculated using multivariate unconditional logistic
regression. Age, levels of triglycerides, cholesterol, CRP,
and body mass index (BMI) were used as continuous
variables in the model. Levels of triglycerides and CRP
were entered into the model after 10log transformation
because these variables were not normally distributed.
Genotypic frequencies for each of the four loci were
determined from the observed genotypic counts, and χ2
analysis was used to check for departures from the
Hardy-Weinberg equilibrium. The association between
the four TAFI SNP and risk of myocardial infarction was
also assessed by means of unconditional logistic regres-
sion. The homozygous genotype of the common allele
was taken as the reference group. SPSS 14.0 (SPSS,
Chicago, IL, USA) was used for all statistical analyses.
Results
The mean age of the 554 patients with myocardial
infarction was 56.4 years (5th-95th percentiles, 40.4-68.8
years) and that of the 643 control subjects was 57.3 (5th-
95th percentiles, 34.7-72.1 years). Arterial risk factors
such as smoking, obesity, diabetes, hypertension, and
hypercholesterolemia were more prevalent in patients
than in control subjects (Table 1). The mean TAFI level
in patients was 84% (5th-95th, percentile 56-112%) and
90% in controls (5th-95th, percentile 58-128%). Age,
BMI, presence of diabetes, smoking, or alcohol use had
no or little effect on TAFI levels (Table 2). Cholesterol
and triglyceride levels were positively associated with
TAFI levels. TAFI levels were 83% in subjects with low
cholesterol levels (first quartile) and 98% in those with
high cholesterol levels (4th quartile). Similarly, TAFI lev-
els increased from 84 to 94% when comparing individ-
uals with low and high triglyceride levels. TAFI levels
also increased with CRP levels (85% for those with low
and 96% for individuals with high CRP). No apparent
association was present with HDL cholesterol or blood
pressure. Multiple linear regression was performed to
determine the independent effect of CRP, total choles-
terol, and triglycerides on TAFI levels. With each
increase in quartile of CRP, TAFI increased 2.8%
(β=2.8%/quartile of CRP; 95% CI 1.4-4.4). For total
cholesterol this was 3.8%/quartile (95% CI 2.3-5.3) and
1.7% (95% CI 0.2-3.2) for triglycerides. Adding smok-
ing to the model did not change the coefficients (data not
shown).
The association between TAFI levels (in quartiles) and
the risk of myocardial infarction is shown in Table 3.
The fourth quartile (highest TAFI levels) was taken as
the reference group. The risk of myocardial infarction
increased with each decreasing quartile. Men with the
lowest TAFI levels (first quartile) had a 2.8-fold age-
adjusted increased risk of myocardial infarction com-
pared with men with TAFI levels in the fourth quartile
Table 1. Characteristics of men with a first myocardial infarction and
control subjects.
Characteristics Patients Control subjects
Number 554 643
Mean age, years 56.4 57.3 
(5th-95th percentile) (40.4-68.8) (34.7-72.1)
Current smoking, n. (%)
No 209 (37.7) 429 (66.7)
Yes 345 (62.3) 214 (33.3)
Alcohol use, n. (%)
Never 85 (15.3) 64 (10.0)
Occasionally 23 (4.2) 21 (3.3)
Regularly 446 (80.5) 558 (86.8)
Body mass index,1 n. (%)
Less than 20 kg/m2 4 (0.7) 10 (1.6)
20-24 kg/m2 151 (27.3) 186 (29.0)
25-29 kg/m2 306 (55.3) 340 (53.0
At least 30 kg/m2 92 (16.6) 106 (16.5)
Diabetes, n. (%)
Absent 528 (95.3) 621 (96.6)
Present 26 (4.7) 22 (3.4)
Hypertension, n. (%)
Absent 450 (81.2) 537 (83.5)
Present 104 (18.8) 106 (16.5)
Hypercholesterolemia, n. (%)
Absent 543 (98.0) 632 (98.3)
Present 11 (2.0) 11 (1.7)
Data for patients refer to the period prior to myocardial infarction,apart from body
mass index. 1Body mass index was unknown for one patient and one control 
subject.
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(OR 2.8; 95% CI 1.9-4.0). Adjusting for other factors
found to be associated with TAFI in the control subjects
(CRP, triglycerides, and cholesterol), resulted in similar
or slightly higher odds ratios (OR 3.4; 95% CI 2.3-5.1).
Further adjustment for BMI, smoking, alcohol use, and
diabetes (full model) did not substantially change the
estimates.
Excluding individuals who were using aspirin at the
time of blood sampling (127 patients and 35 control
subjects) did not change the results, nor did excluding
the 132 patients who used oral anticoagulants at the
time of blood collection (data not shown).
We also investigated the effect of the combination of
low TAFI levels and smoking or increased CRP levels
on the risk of myocardial infarction. Table 4 shows the
risk of myocardial infarction for quartiles of TAFI in
smokers and non-smokers. The reference group was
formed of the non-smokers with the highest levels (4th
quartile) of TAFI, who had the lowest risk of myocar-
dial infarction. Within the non-smokers, decreased
TAFI levels (1st quartile) were associated with an almost
two-fold increased risk of myocardial infarction (OR
1.9; 95% CI 1.1-3.2). In men who smoked and had high
TAFI levels (4th quartile) an OR of 2.1 was found (95%
CI 1.1-3.7). Smokers with TAFI levels in the 1st quartile
had a risk of myocardial infarction that was increased
9.4-fold (95% CI 5.4-16.4). The odds ratios were 2.8
(95% CI 1.8-4.4) for men with low TAFI levels and a
CRP level below the 75th percentile, 1.9 (95% CI 1.0-
3.5) for those with CRP levels above the 75th percentile
and high TAFI levels, and the risk of myocardial infarc-
tion was increased 8.2-fold (95% CI 4.4-15.2) in men
with high CRP levels and low TAFI levels, all compared
with men with low CRP and high TAFI levels.
Table 5 shows the risk of myocardial infarction asso-
ciated with four SNP in the TAFI gene as well as mean
TAFI level for each genotype. The observed frequency
distribution of the TAFI genotypes in the control group
did not deviate from that predicted for the four SNP
under the Hardy-Weinberg equilibrium. The SNP at
position -438, 505, and 1040 were strongly associated
with TAFI levels. The mean TAFI level in those subjects
carrying the -438GG genotype was 94%, while the
mean TAFI level in carriers of the -438AA genotype
was 76%. Mean TAFI level was 82% for carriers of the
505GG genotype and 107% for those with the 505AA
genotype. Individuals with the 1040CC genotype had a
mean TAFI level of 94%, which was higher than that of
subjects with the 1040TT genotype (mean TAFI level
75%). The association between the i4 + 164A/C SNP
and TAFI levels was less clear. Carriers of the -438AA
Table 2. Arterial risk factors among control subjects and the associ-
ation with TAFI levels.
N. of control subjects Mean TAFI% 
(total=643) (5-95th percentile)
Age (years)
27-39 56 85 (36-124)
40-49 104 91 (40-138)
50-59 179 95 (68-133)
60-69 247 89 (58-124)
70-75 57 85 (52-112)
Body mass index (kg/m2)1
Less than 25 196 87 (58-125)
25-29 340 92 (59-130)
at least 30 106 92 (59-126)
Diabetes
Absent 621 91 (60-128)
Present 22 84 (50-128)
Current smoking
No 429 89 (58-124)
Yes 214 93 (60-133)
Alcohol use
Never 64 87 (54-121)
Occasionally 21 91 (64-127)
Regularly 558 91 (58-129)
Diastolic blood pressure (mmHg)2
80 or less 199 89 (60-125)
85 93 92 (63-128)
90 169 90 (59-131)
At least 95 177 91 (53-133)
Systolic blood pressure (mmHg)2
125 or less 158 88 (58-123)
130-135 113 89 (63-129)
140-150 205 93 (60-137)
At least 155 162 89 (57-125)
Triglycerides (mmol/L)1
Less than 0.90 162 84 (55-122)
0.90-1.24 162 89 (59-120)
1.25-1.82 160 95 (66-129)
At least 1.83 158 94 (58-133)
Total cholesterol (mmol/L)1
Less than 5.17 164 83 (54-122)
5.17-5.81 159 89 (58-128)
5.82-6.59 160 91 (64-126)
At least 6.60 159 98 (64-139)
HDL cholesterol (mmol/L)3
Less than 1.1 160 87 (53-124)
1.1-1.28 159 93 (58-130)
1.29-1.53 163 91 (65-124)
At least 1.54 158 90 (57-130)
CRP (mg/L)
Less than 0.78 161 85 (58-118)
0.78-1.55 161 89 (58-130)
1.56-3.42 160 92 (64-133)
At least 3.43 161 96 (62-129)
1Information about BMI, total cholesterol, and triglycerides was unavailable for one
control subject. 2Information about diastolic and systolic blood pressure was
unavailable for five control subjects. 3Information about HDL-cholesterol was
unavailable for three control subjects.
Table 3. Risk of myocardial infarction with decreasing quartile of
TAFI level.
Quartile of TAFI- 4 (ref.) 3 2 1
activity level
TAFI-activity (range) 102-161 89-101 76-88 19-75
N. of cases 65 132 172 185
N. of control subjects 156 157 168 162
ORadj (95% CI)1 1 2.1 2.5 2.8
(1.4-3.0) (1.8-3.6) (1.9-4.0)
ORadj (95% CI)2 1 2.3 3.0 3.5
(1.6-3.4) (2.1-4.4) (2.4-5.1)
ORadj (95% CI)3 1 2.4 3.2 3.4
(1.6-3.6) (2.1-4.7) (2.3-5.1)
CI: confidence interval; 1ORadj: Odds ratio adjusted for age. 2ORadj: Odds ratio 
adjusted for age,CRP, triglycerides,and total cholesterol. 3ORadj: Odds ratio adjusted
for age,CRP, triglycerides, total cholesterol,BMI, smoking,alcohol use,and diabetes.
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genotype, who had low TAFI levels, had an increased
risk of myocardial infarction (OR 1.6; 95% CI 1.0-2.5)
compared with carriers of the -438GG genotype. The
odds ratio for carriers of the -438AG genotype was 1.2
(0.9-1.5). The other SNP appeared not to be associated
with risk.
Results of several studies on the association between
levels of TAFI and risk of myocardial infarction were, in
retrospect, considered not reliable as assays depended
on the 1040C/T genotype. To verify whether the asso-
ciation between low TAFI activity and myocardial
infarction was independent of the 1040T allele, the
association of TAFI levels and myocardial infarction
was determined only in those men who carried the
1040CC genotype. Among men carrying the 1040CC
genotype, the age-adjusted odds ratio for myocardial
infarction among those with TAFI levels in the first
quartile was 2.0 (95% CI 1.2-3.3), compared with those
with TAFI levels in the fourth quartile. Using the full
model, the odds ratio was 2.2 (95% CI 1.2-3.9).
Discussion
This case-control study shows that individuals with
low TAFI levels, as measured with a functional assay,
had an increased risk of a first myocardial infarction
compared with those with high TAFI levels. In accor-
dance with these results, individuals carrying the A
allele of the -438A/G SNP in the promoter region of the
TAFI gene, who have low TAFI levels, had an increased
risk of myocardial infarction, compared with individu-
als carrying the GG genotype. The 505G/A and
1040C/T polymorphisms, which are also associated
with levels of TAFI activity, were not associated with
the risk of myocardial infarction.
The increased risk of myocardial infarction in men
with lower TAFI levels remained after adjusting for sev-
eral arterial risk factors, some of which (i.e., triglyc-
erides and total cholesterol) were shown to be strongly
associated with TAFI levels. The increased risk was
found to be independent of the 1040T allele. A dose-
response association was found between TAFI levels
and myocardial infarction, but the risk difference
between the third and fourth quartile was most pro-
nounced while the odds ratios for the first, second and
third quartiles were similar. In other words, there might
be a threshold, above which levels of TAFI protect
against myocardial infarction. 
The results of our study partly contrast those of pre-
vious studies and are not in line with what would be
expected based on the role of TAFI in the regulation of
fibrinolysis. Several case-control studies have found
increased TAFI levels to increase the risk of coronary
artery disease or myocardial infarction13,14,16 or did not
find any association between TAFI and arterial throm-
bosis.26 Explanations for these differences could be dif-
ferent outcome measures,13,14,26 inclusion of men and
women,13,14,16,26 restriction to a relatively young popula-
tion,16 or blood sampling during the acute phase of the
disease.14 In some studies comparisons were only made
between mean TAFI levels of patients and controls and
thus extreme values were not studied and adjustments
for possible confounders that could have influenced the
Table 4. Combined risk of myocardial infarction by quartiles of TAFI
and smoking status.
TAFI N. of N. of control ORadj
(%, range) cases subjects (95% CI)1
Smoking
No 102-161 25 88 1 (ref.)
89-101 47 112 1.5 (0.8-2.6)
76-88 75 113 2.3 (1.4-4.0)
19-75 62 116 1.9 (1.1-3.2)
Yes 102-161 40 68 2.1 (1.1-3.7)
89-101 85 45 6.6 (3.7-11.8)
76-88 97 55 6.2 (3.6-10.8)
19-75 123 46 9.4 (5.4-16.4)
CRP
<75th percentile 102-161 35 104 1 (ref.)
89-101 84 110 2.4 (1.5-3.8)
76-88 112 130 2.7 (1.7-4.3)
19-75 125 138 2.8 (1.8-4.5)
>75th percentile 102-161 30 52 1.9 (1.0-3.5)
89-101 48 47 3.4 (1.9-5.9)
76-88 60 38 5.3 (3.0-9.3)
19-75 60 24 8.2 (4.4-15.2)
1ORadj =Odds ratio adjusted for age; CI=confidence interval.
Table 5. Effect of TAFI SNP on functional TAFI levels and on risk of
myocardial infarction.
SNP Cases (%) Controls (%) TAFI (%)1, ORadj
(n=554) (n=643) mean (95% CI)
(5-95th percentile)
-438
GG 297 (53.6) 378 (58.8) 94 (66-131) 12
AG 215 (38.8) 231 (35.9) 86 (58-120) 1.2 (0.9-1.5)
AA 42 (7.6) 34 (5.3) 76 (58-98) 1.6 (1.0-2.5)
i4 + 164
AA 203 (36.6) 237 (36.9) 93 (60-137) 12
AC 274 (49.5) 301 (46.8) 88 (57-124) 1.1 (0.8-1.4)
CC 77 (13.9) 105 (16.3) 89 (68-118) 0.9 (0.6-1.2)
505
GG 264 (47.7) 297 (46.2) 82 (55-111) 12
AG 236 (42.6) 282 (43.9) 95 (68-127) 0.9 (0.7-1.2)
AA 54 (9.7) 64 (10.0) 107 (39-153) 0.9 (0.6-1.4)
1040
CC 269 (48.6) 310 (48.2) 94 (66-133) 12
CT 233 (42.1) 285 (44·3) 88 (58-123) 0.9 (0.7-1.2)
TT 52 (9.4) 48 (7.5) 75 (54-99) 1.2 (0.8-1.9)
ORadj: Odds ratio adjusted for age; CI: confidence interval. 1TAFI levels in control
subjects.2reference group.
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results were not performed.14,16 In one case-control
study TAFI antigen levels were decreased in patients
with myocardial infarction but activity levels of TAFI
were increased, a difference that could not be explained
by the 1040C/T SNP.16 In the PRIME-study, a large
prospective cohort study set up to investigate potential
reasons for the difference in incidence of coronary
heart disease in France and Northern Ireland, no clear
association was found between baseline TAFI levels
and angina pectoris or myocardial infarction and coro-
nary death. However, in this study TAFI was measured
with an antigen and not activity assay. Surprisingly, the
505A allele, which is associated with increased TAFI
levels, was associated with an increased risk of coro-
nary heart disease in France but with a decreased risk in
Northern Ireland.27 The HIFMECH study, a European
multicenter case-control study, found elevated TAFI
levels to be associated with a decreased risk of myocar-
dial infarction, confirmed by a higher frequency of the
505A allele in patients than in controls.15 The TAFI anti-
gen assay used in the HIFMECH study was later found
to be dependent on the 1040C/T genotype. 
Although TAFI has been shown to inhibit fibrinolysis
in vivo, recent studies suggest that TAFI plays an impor-
tant role in regulating complement-mediated vascular
inflammation in vivo. TAFI inhibits inflammation in vivo
by inactivating the inflammatory mediators bradykinin
and the anaphylatoxins C3a and C5a.19 Furthermore,
TAFI–/– plasminogen+/– mice expressed increased leuko-
cyte migration compared with their wild-type counter-
parts in a model of peritoneal inflammation.28 In anoth-
er study, TAFI-deficient mice, primed by lipopolysac-
charide, showed increased mortality after infusion of
cobra venom factor, which is a potent non-specific acti-
vator of complement proteins.29 Based on these results,
one might expect that TAFI-deficient mice would have
a more rapid progression of atherosclerosis, in which
inflammation plays a pivotal role. However, to our
knowledge, no data on atherosclerosis progression in
TAFI knockout mice are available. As inflammation
plays an important role in the development of athero-
sclerosis and arterial thrombosis,30 it is not implausible
that increased TAFI levels decrease the risk of myocar-
dial infarction by decreasing the inflammatory
response. These two counteracting effects may also
explain the conflicting study results on TAFI and arteri-
al thrombosis, and, because inflammation is less impor-
tant in venous disease, the consistent relation between
high TAFI levels and venous thrombosis risk. There is
also evidence that TAFI binds to collagen resulting in
reduced platelet adhesion to collagen under flow condi-
tions,31 which could also contribute to the protective
effect of TAFI.
The high risk of myocardial infarction found in
smokers with low TAFI levels is also in line with an
excessive inflammatory response. It is known that
smoking leads to an inflammatory state,32 a fact also
supported by increased CRP levels in smokers com-
pared to non-smokers in this study.25 It is possible that
the effect of smoking on risk of myocardial infarction is
most pronounced in those individuals with decreased
TAFI levels, who have reduced potential to neutralize
this inflammatory response. This hypothesis is also
supported by the 8.2-fold increased risk in men with
high levels of CRP, indicating elevated inflammatory
state, and low TAFI levels. In addition to smoking and
increased CRP levels, hypercholesterolemia is also
associated with an increased inflammatory state.33 A
large number of patients, however, were using lipid-
lowering drugs at the time of blood sampling, making
an analysis on the combination of cholesterol and TAFI
levels unreliable. The data on hypercholesterolemia
based on the use of lipid-lowering drugs prior to
myocardial infarction (Table 1) were insufficient for
such an analysis.
We found a higher risk in individuals carrying the -438A
allele than in those carrying the -438G allele, which
supports our finding that decreased TAFI levels increase
the risk of myocardial infarction. No clear increase in
risk was found for those carrying the 1040T allele com-
pared with the 1040C, while both the -438A and 1040T
alleles appeared to decrease TAFI levels. It is known
that the 1040 T for C substitution results in a TAFIa
species with a prolonged half-life at 37°C.34 Possibly,
this increased stability of TAFIa compensates for the
decreased levels of the protein.
Surprisingly, the 505G/A SNP (or Ala147Thr), which
has the largest effect on TAFI levels, was not associated
with the risk of myocardial infarction. It could be that
this SNP has an unknown function that counteracts the
protective effect of the increased levels. The TAFI crys-
tal structure shows that the amino acid at position 147
is solvent exposed.35 Thus, theoretically, this residue,
which is located close to the Arg145 that is known to
be one of the essential residues for substrate peptide
anchoring,36 might contribute to ligand binding and the
505G/A polymorphism might affect this process.
Although the 505G/A polymorphism does not affect
TAFI fibrinolytic activity,34 the effect of the polymor-
phism on the catalytic activity towards other molecular
substrates such as bradykinin and anaphylatoxins has,
to our knowledge, not yet been tested. A decreased
activity of the A variant towards TAFI substrates
involved in inflammation could plausibly explain why
no association is found between the 505G/A SNP and
the risk of myocardial infarction. Another possibility is
that it is not the 505G/A SNP itself that is the function-
al variant but that this SNP is in strong linkage disequi-
librium with another functional SNP. It has been sug-
gested that the 505G/A SNP is not directly related to
TAFI levels but that the 1583T>A SNP, which is in
strong linkage disequilibrium with the 505G/A SNP, is
actually the functional variant.24 Similarly, the -438G/A
might itself not be functional.37 However, the linkage
between SNP in the TAFI gene is so strong that the
results of the SNP measured in our study are reliable
indicators of the effects of the putative functional SNP. 
It is possible that reduced TAFI levels are not causal-
ly linked to an increased risk of myocardial infarction,
but that TAFI levels are reduced by another causal fac-
tor preceding the myocardial infarction. We are not
aware of any risk factor for myocardial infarction that
would reduce TAFI levels. The only disease state that
could lead to low TAFI levels would be liver disease,
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which was only present in two cases and three controls,
who had normal TAFI levels. Furthermore, TAFI levels
were found to increase with risk factors for myocardial
infarction, such as lipid levels and CRP, rather than
decrease. As TAFI is also suggested to be an acute phase
protein38 it is not likely that decreased TAFI levels are a
result of some other underlying factor. Samples were
frozen and stored for approximately 10 years. This
could have influenced the levels of TAFI. However, if
TAFI activity decreases during storage this effect would
be equal in patients and controls so no bias of the results
is expected, or at most an attenuation of the observed
effects.
In conclusion, our study provides evidence that
decreased TAFI levels are associated with an increased
risk of a first myocardial infarction in men. The results
on the association between TAFI SNP and myocardial
infarction were inconsistent.
Authorship and Disclosures
MEM designed the study, analyzed and interpreted
the data, and drafted the manuscript; CJMD designed
the overall study, collected and interpreted the data, and
critically reviewed the analyses and the manuscript;
PGdG interpreted the data and critically reviewed the
analyses and the manuscript; JCMM designed the pres-
ent study, was responsible for performing the assay,
interpreted the data and critically reviewed the analyses
and the manuscript; FRR designed the overall study,
interpreted the data, and critically reviewed the analy-
ses and the manuscript; TL designed the study, inter-
preted the data, critically reviewed the analyses and
participated in writing the manuscript.
The authors declare that they have no conflicts of
interest. 
References
1. Mosnier LO, Bouma BN. Regulation
of fibrinolysis by thrombin activat-
able fibrinolysis inhibitor, an unsta-
ble carboxypeptidase B that unites
the pathways of coagulation and fib-
rinolysis. Arterioscler Thromb Vasc
Biol 2006;26:2445-53.
2. Minnema MC, Friederich PW, Levi
M, von dem Borne PA, Mosnier LO,
Meijers JCM, et al. Enhancement of
rabbit jugular vein thrombolysis by
neutralization of factor XI. In vivo
evidence for a role of factor XI as an
anti-fibrinolytic factor. J Clin Invest
1998;101:10-4.
3. Redlitz A, Nicolini FA, Malycky JL,
Topol EJ, Plow EF. Inducible car-
boxypeptidase activity. A role in clot
lysis in vivo. Circulation 1996;93:
1328-30.
4. Klement P, Liao P, Bajzar L. A novel
approach to arterial thrombolysis.
Blood 1999;94:2735-43.
5. Wang YX, da Cunha V, Vincelette J,
Zhao L, Nagashima M, Kawai K, et
al. A novel inhibitor of activated
thrombin activatable fibrinolysis
inhibitor (TAFIa) - part II: enhance-
ment of both exogenous and endo-
genous fibrinolysis in animal models
of thrombosis. Thromb Haemost
2007;97:54-61.
6. van Tilburg NH, Rosendaal FR,
Bertina RM. Thrombin activatable
fibrinolysis inhibitor and the risk for
deep vein thrombosis. Blood 2000;
95:2855-9.
7. Eichinger S, Schönauer V, Welter-
mann A, Minar E, Bialonczyk C,
Hirschl M, et al. Thrombin-activat-
able fibrinolysis inhibitor and the
risk for recurrent venous throm-
boembolism. Blood 2004;103:3773-
6.
8. Libourel EJ, Bank I, Meinardi JR,
Baljé-Volkers CP, Hamulyak K,
Middeldorp S, et al. Co-segregation
of thrombophilic disorders in factor
V Leiden carriers; the contributions
of factor VIII, factor XI, thrombin
activatable fibrinolysis inhibitor and
lipoprotein(a) to the absolute risk of
venous thromboembolism. Haema-
tologica 2002;87:1068-73.
9. Franco RF, Fagundes MG, Meijers
JCM, Reitsma PH, Lourenço D,
Morelli V, et al. Identification of
polymorphisms in the 5'-untranslat-
ed region of the TAFI gene: relation-
ship with plasma TAFI levels and risk
of venous thrombosis. Haematolo-
gica 2001;86:510-7.
10. Morange PE, Aillaud MF, Nicaud V,
Henry M, Juhan-Vague I. Ala147Thr
and C+1542G polymorphisms in the
TAFI gene are not asssociated with a
higher risk of venous thrombosis in
FV Leiden carriers. Thromb Haemost
2001;86:1583-4.
11. Martini CH, Brandts A, de Bruijne
EL, van Hylckama Vlieg A, Leebeek
FWG, Lisman T, Rosendaal FR. The
effect of genetic variants in the
thrombin activatable fibrinolysis
inhibitor (TAFI) gene on TAFI-anti-
gen levels, clot lysis time and the risk
of venous thrombosis. Br J Haematol
2006;134:92-4.
12. Silveira A, Schatteman K, Goossens
F, Moor E, Scharpé S, Strömqvist M,
et al. Plasma procarboxypeptidase U
in men with symptomatic coronary
artery disease. Thromb Haemost
2000;84:364-8.
13. Santamaría A, Martínez-Rubio A,
Borrell M, Mateo J, Ortín R,
Fontcuberta J. Risk of acute coronary
artery disease associated with func-
tional thrombin activatable fibrinoly-
sis inhibitor plasma level.
Haematologica 2004;89:880-1.
14. Schroeder V, Wilmer M, Buehler B,
Kohler HP. TAFI activity in coronary
artery disease: a contribution to the
current discussion on TAFI assays.
Thromb Haemost 2006;96:236-7.
15. Juhan-Vague I, Morange PE, Aubert
H, Henry M, Aillaud MF, Alessi MC,
et al. Plasma thrombin-activatable
fibrinolysis inhibitor antigen concen-
tration and genotype in relation to
myocardial infarction in the north
and south of Europe. Arterioscler
Thromb Vasc Biol 2002;22:867-73.
16. Zorio E, Castelló R, Falcó C, España
F, Osa A, Almenar L, et al.
Thrombin-activatable fibrinolysis
inhibitor in young patients with
myocardial infarction and its rela-
tionship with the fibrinolytic func-
tion and the protein C system. Br J
Haematol 2003;122:958-65.
17. Brouwers GJ, Leebeek FWG, Tanck
MW, Wouter Jukema J, Kluft C, de
Maat MP. Association between
thrombin-activatable fibrinolysis
inhibitor (TAFI) and clinical outcome
in patients with unstable angina pec-
toris. Thromb Haemost 2003;90:92-
100.
18. Boffa MB, Koschinsky ML. Curious-
er and curiouser: recent advances in
measurement of thrombin-activat-
able fibrinolysis inhibitor (TAFI) and
in understanding its molecular genet-
ics, gene regulation, and biological
roles. Clin Biochem 2007;40:431-42.
19. Myles T, Nishimura T, Yun TH,
Nagashima M, Morser J, Patterson
AJ, et al. Thrombin activatable fibri-
nolysis inhibitor, a potential regula-
tor of vascular inflammation. J Biol
Chem 2003;278:51059-67.
20. Fogg DK, Bridges DE, Cheung KK,
Kassam G, Filipenko NR, Choi KS, et
al. The p11 subunit of annexin II het-
erotetramer is regulated by basic car-
boxypeptidase. Biochemistry 2002;
41:4953-61.
21. Gils A, Alessi MC, Brouwers E,
Peeters M, Marx P, Leurs J, et al.
Development of a genotype 325-spe-
cific proCPU/TAFI ELISA. Arterio-
scler Thromb Vasc Biol 2003;23:
1122-7.
22. Henry M, Aubert H, Morange PE,
Nanni I, Alessi MC, Tiret L, Juhan-
Vague I. Identification of polymor-
phisms in the promoter and the 3'
region of the TAFI gene: evidence
M.E. Meltzer et al. 
| 818 | haematologica | 2009; 94(6)
that plasma TAFI antigen levels are
strongly genetically controlled.
Blood 2001;97:2053-8.
23. Brouwers GJ, Vos HL, Leebeek
FWG, Bulk S, Schneider M, Boffa M,
et al. A novel, possibly functional,
single nucleotide polymorphism in
the coding region of the thrombin-
activatable fibrinolysis inhibitor
(TAFI) gene is also associated with
TAFI levels. Blood 2001;98:1992-3.
24. Frère C, Tregouet DA, Morange PE,
Saut N, Kouassi D, Juhan-Vague I, et
al. Fine mapping of quantitative trait
nucleotides underlying thrombin-
activatable fibrinolysis inhibitor
antigen levels by a transethnic
study. Blood 2006;108:1562-8.
25. Doggen CJM, Berckmans RJ, Sturk
A, Manger Cats V, Rosendaal FR. C-
reactive protein, cardiovascular risk
factors and the association with
myocardial infarction in men. J
Intern Med 2000;248:406-14.
26. Folkeringa N, Coppens M, Veeger
NJ, Bom VJ, Middeldorp S,
Hamulyak K, et al. Absolute risk of
venous and arterial thromboem-
bolism in thrombophilic families is
not increased by high thrombin-
activatable fibrinolysis inhibitor
(TAFI) levels. Thromb Haemost
2008;100:38-44.
27. Morange PE, Tregouet DA, Frere C,
Luc G, Arveiler D, Ferrieres J, et al.
TAFI gene haplotypes, TAFI plasma
levels and future risk of coronary
heart disease: the PRIME Study. J
Thromb Haemost 2005;3:1503-10.
28. Swaisgood CM, Schmitt D, Eaton
D, Plow EF. In vivo regulation of
plasminogen function by plasma
carboxypeptidase B. J Clin Invest
2002;110:1275-82.
29. Asai S, Sato T, Tada T, Miyamoto T,
Kimbara N, Motoyama N, et al.
Absence of procarboxypeptidase R
induces complement-mediated
lethal inflammation in lipopolysac-
charide-primed mice. J Immunol
2004;173:4669-74.
30. Libby P. Inflammation in atheroscle-
rosis. Nature 2002;420:868-74.
31. Marx PF, Lisman T, Adelmeijer J,
Marquart J, Meijers JCM. Binding of
TAFI to collagen: a role for TAFI in
the regulation of platelet adhesion? J
Thromb Haemost 2006;4(Suppl 1):
208.
32. Bazzano LA, He J, Muntner P,
Vupputuri S, Whelton PK. Relation-
ship between cigarette smoking and
novel risk factors for cardiovascular
disease in the United States. Ann
Intern Med 2003;138: 891-7.
33. Stokes KY, Cooper D, Tailor A,
Granger DN. Hypercholesterolemia
promotes inflammation and micro-
vascular dysfunction: role of nitric
oxide and superoxide. Free Radic
Biol Med 2002;33:1026-36.
34. Schneider M, Boffa M, Stewart R,
Rahman M, Koschinsky M,
Nesheim M. Two naturally occur-
ring variants of TAFI (Thr-325 and
Ile-325) differ substantially with
respect to thermal stability and
antifibrinolytic activity of the
enzyme. J Biol Chem 2002;277:
1021-30.
35. Marx PF, Brondijk THC, Plug T,
Romijn RA, Hemrika W, Meijers
JCM, Huizinga EG. Crystal struc-
tures of TAFI elucidate the inactiva-
tion mechanism of activated TAFI: a
novel mechanism for enzyme
autoregulation. Blood 2008;112:
2803-9.
36. Avilés FX, Vendrell J, Guasch A, Coll
M, Huber R. Advances in metallo-
procarboxypeptidases. Emerging
details on the inhibition mechanism
and on the activation process. Eur J
Biochem. 1993; 211:381-9.
37. Boffa MB, Maret D, Hamill JD,
Bastajian N, Crainich P, Jenny NS, et
al. Effect of single nucleotide poly-
morphisms on expression of the
gene encoding thrombin-activatable
fibrinolysis inhibitor: a functional
analysis. Blood 2008;111:183-9.
38. Sato T, Miwa T, Akatsu H,
Matsukawa N, Obata K, Okada N,
et al. Pro-carboxypeptidase R is an
acute phase protein in the mouse,
whereas carboxypeptidase N is not.
J Immunol 2000;165:1053-8.
